abstract |
The invention relates to a method for treating human growth hormone (hGH) fusion protein (GX-H9) of growth hormone deficiency. More specifically, the present invention relates to a pharmaceutical composition for treating growth hormone deficiency, comprising a hGH fusion protein and a pharmaceutically acceptable carrier, wherein the fusion protein is at a dose of 0.4 mg to 1.6 mg per kg body weight of a child patient per week It is administered once, or every two weeks at a dose of 0.8 mg to 3.2 mg per kg of body weight in a child patient. In addition, the present invention relates to a method for treating growth hormone deficiency, comprising administering an hGH fusion protein to a patient suffering from growth hormone deficiency, and administering it once a week at a dose of 0.4 mg to 1.6 mg per kg of body weight, or A dose of 0.8 mg to 3.2 mg per kg of body weight is administered every two weeks. |